LELANTOS II Duchenne Muscular Dystrophy Study
Publication date: 11 Feb 2022
Associated community Muscular Dystrophy, Duchenne and Becker Types
You and your loved one are not alone in managing Duchenne muscular dystrophy. The LELANTOS II study is evaluating an investigational drug in patients with Duchenne muscular dystrophy who can walk without braces or assistive devices. The study is evaluating whether the drug can maintain or improve muscle strength of upper extremities and stabilize respiratory and heart functions in Duchenne patients.
Duchenne patients who fit the following criteria may be eligible to participate:
-
A Duchenne muscular dystrophy diagnosis
-
Male
-
6-11 years old
-
Currently able to walk without braces or assistive devices
-
On a stable dose of corticosteroids for at least 6 months
Duchenne research can only move forward with volunteers. Answer a few questions to see if your loved one is eligible to take part in this clinical study: http://https://antidote.me/prescreener/s/en-US/duchenne_muscular_dystrophy-159?utm_source=Rareshare&utm_medium=referral&utm_campaign=E15
Thank you for your interest!